Q2 2026 13F · SEC CIK 1816307

Silverarc Capital Management, LLC

Hedge fundFiled 2026-08-13 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $898.5M
Reported positions: 65
Top holdings a year, 3 yrs: +51.5%
Assets under management: $1.6B

Silverarc Capital Management, LLC is a hedge fund that reported 65 positions worth $898.5M in its Q2 2026 13F, filed 2026-08-13. Its largest holdings were Ascendis Pharma A/s (ASND, 6.1%), Celcuity Inc (CELC, 5.8%), Cogent Biosciences Inc (COGT, 5.5%). A portfolio copying its top holdings returned 51.5% a year over the last 3 years, against 22.3% for the S&P 500.

Silverarc Capital Management, LLC holdings largest 50 of 65 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Silverarc Capital Management, LLC 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
ASNDAscendis Pharma A/s	6.1%	—	206,234	—	$55.0M
CELCCelcuity Inc	5.8%	4.8%	500,996	+40.0%	$52.4M
COGTCogent Biosciences Inc	5.5%	6.0%	1,280,707	-2.5%	$49.6M
URGNUrogen Pharma Ltd	5.3%	3.2%	1,301,979	-13.4%	$47.9M
IMNMImmunome Inc	4.8%	4.8%	2,017,009	+9.0%	$42.7M
DNTHDianthus Therapeutics Inc	4.2%	6.5%	390,000	-40.4%	$38.0M
RYTMRhythm Pharmaceuticals Inc	3.8%	3.1%	311,461	+1.8%	$34.6M
ORKAOruka Therapeutics Inc	3.7%	0.9%	352,802	+133.8%	$33.6M
GLUEMonte Rosa Therapeutics Inc	3.0%	3.9%	1,108,295	-44.6%	$26.8M
SNDXSyndax Pharmaceuticals Inc	3.0%	2.4%	1,214,390	+36.6%	$26.5M
ELVNEnliven Therapeutics Inc	2.8%	—	489,382	—	$24.8M
IMVTImmunovant Inc	2.7%	1.2%	619,096	+49.5%	$23.9M
ERASErasca, Inc.	2.6%	3.5%	1,263,026	-31.8%	$23.1M
SGMTSagimet Biosciences Inc	2.5%	—	2,927,698	—	$22.6M
ABVXAbivax SA	2.5%	4.0%	169,593	-43.9%	$22.6M
PRAXPraxis Precision Medicines I	2.4%	2.7%	65,679	-8.2%	$22.0M
KODKodiak Sciences Inc	2.4%	4.5%	546,256	-44.9%	$21.3M
24477V105Definium Therapeutics Inc	2.1%	—	400,000	—	$18.8M
VCYTVeracyte Inc	2.1%	0.7%	318,001	+77.0%	$18.7M
GHGuardant Health Inc	1.7%	1.1%	99,826	+1.3%	$15.0M
CCCCC4 Therapeutics Inc	1.6%	0.6%	3,032,060	+58.6%	$14.2M
ZBIOZenas Biopharma Inc	1.4%	2.6%	509,789	-55.1%	$12.9M
TRVITrevi Therapeutics Inc	1.4%	0.7%	678,095	+32.7%	$12.6M
HLXCHelix Acquisition Corp III	1.4%	1.4%	1,177,821	-2.6%	$12.5M
ALXOAlx Oncology Hldgs Inc	1.3%	—	5,744,757	—	$11.9M
MANEVeradermics Inc	1.3%	—	95,000	—	$11.7M
XENEXenon Pharmaceuticals Inc	1.3%	1.4%	186,821	-5.5%	$11.3M
AVLNAvalyn Pharmaceuticals Inc	1.2%	—	330,487	—	$10.9M
BIIBBiogen Inc	1.2%	1.1%	48,101	-5.6%	$10.4M
ACRSAclaris Therapeutics Inc	1.1%	—	1,946,482	—	$10.3M
CERSCerus Corp	1.1%	0.7%	3,472,737	+9.3%	$10.1M
AVTXAvalo Therapeutics Inc	1.0%	—	500,402	—	$9.2M
BNTCBenitec Biopharma Inc	1.0%	0.9%	679,826	-5.3%	$9.1M
PCVXVaxcyte Inc	0.9%	1.0%	145,000	+0.0%	$8.4M
WGSGenedx Holdings Corp	0.9%	—	122,269	—	$8.4M
SVRASavara Inc	0.9%	0.9%	1,355,459	-5.3%	$8.3M
OVIDOvid Therapeutics Inc	0.9%	—	3,101,129	—	$8.3M
ORICOric Pharmaceuticals Inc	0.9%	1.6%	738,873	-32.8%	$8.0M
CMPSCompass Pathways PLC	0.8%	—	503,382	—	$7.1M
CGENCompugen Ltd	0.8%	0.8%	3,184,257	-4.0%	$6.8M
SLDBSolid Bioscience Inc.	0.7%	—	668,450	—	$6.7M
IBIOIbio Inc	0.7%	—	3,520,490	—	$6.2M
IRONDisc Medicine Inc	0.7%	1.5%	82,800	-57.8%	$6.1M
ALKSAlkermes PLC	0.7%	1.9%	113,494	-75.3%	$5.9M
SYRESpyre Therapeutics	0.6%	1.1%	59,959	-67.9%	$5.3M
ARTVArtiva Biotherapeutics Inc	0.6%	—	525,000	—	$5.1M
CTNMContineum Therapeutics Inc	0.5%	0.5%	296,135	-1.9%	$4.9M
QUREUniqure NV	0.5%	—	105,000	—	$4.8M
RACCResearch Alliance Corp III	0.4%	—	360,000	—	$3.9M
ABEOAbeona Therapeutics	0.4%	0.3%	610,407	-5.9%	$3.8M

What Silverarc Capital Management, LLC bought and sold in Q2 2026, against Q1 2026.

New positions

Q1 2026's filing was too long to tell new positions apart.

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +37.7% /yr; S&P 500 +11.7%
3 years: +51.5% /yr; S&P 500 +22.3%
5 years: +18.4% /yr; S&P 500 +10.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$898.5M	65
Q1 2026	$848.6M	67
Q4 2025	$691.1M	64
Q3 2025	$690.7M	73
Q2 2025	$488.6M	57
Q1 2025	$478.6M	67
Q4 2024	$447.2M	58
Q3 2024	$443.8M	68
Q2 2024	$405.1M	66
Q1 2024	$356.6M	73
Q4 2023	$324.2M	64
Q3 2023	$268.4M	68

Questions about Silverarc Capital Management, LLC's portfolio

What stocks does Silverarc Capital Management, LLC own?

Silverarc Capital Management, LLC's latest 13F, for Q2 2026 and filed Aug 13, 2026, lists 65 positions worth $898.5M. The largest are Ascendis Pharma A/s (ASND) at 6.1%, Celcuity Inc (CELC) at 5.8%, Cogent Biosciences Inc (COGT) at 5.5%, Urogen Pharma Ltd (URGN) at 5.3% and Immunome Inc (IMNM) at 4.8%.

What did Silverarc Capital Management, LLC buy last quarter?

In Q2 2026, Silverarc Capital Management, LLC added Oruka Therapeutics Inc (ORKA) (+133.8% shares), Veracyte Inc (VCYT) (+77.0% shares) and C4 Therapeutics Inc (CCCC) (+58.6% shares), compared with its Q1 2026 filing.

What did Silverarc Capital Management, LLC sell last quarter?

In Q2 2026, Silverarc Capital Management, LLC cut from its top 50 Kalvista Pharmaceuticals Inc (KALV), cut from its top 50 Nuvalent Inc (NUVL), cut from its top 50 Ascendis Pharma A/s, cut from its top 50 Centessa Pharmaceuticals PLC (CNTA), cut from its top 50 Scholar Rock Hldg Corp (SRRK), Alkermes PLC (ALKS) (-75.3% shares), Spyre Therapeutics (SYRE) (-67.9% shares) and Disc Medicine Inc (IRON) (-57.8% shares), compared with its Q1 2026 filing.

How has Silverarc Capital Management, LLC's portfolio performed?

A portfolio copying Silverarc Capital Management, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +51.5% a year over the last 3 years, against +22.3% for the S&P 500. Over 1 year: +37.7% against +11.7%. Over 5 years: +18.4% a year against +10.6%.

When is Silverarc Capital Management, LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. Silverarc Capital Management, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Silverarc Capital Management, LLC manage?

Silverarc Capital Management, LLC reported $1.6B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $898.5M.